Bank of America Corp DE Increases Stake in ADMA Biologics, Inc. (NASDAQ:ADMA)

Bank of America Corp DE raised its stake in shares of ADMA Biologics, Inc. (NASDAQ:ADMA - Free Report) by 59.7% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 766,224 shares of the biotechnology company's stock after buying an additional 286,569 shares during the quarter. Bank of America Corp DE owned about 0.32% of ADMA Biologics worth $13,141,000 at the end of the most recent quarter.

Other large investors have also added to or reduced their stakes in the company. Mark Sheptoff Financial Planning LLC purchased a new stake in ADMA Biologics during the 4th quarter valued at $35,000. Vision Financial Markets LLC bought a new position in shares of ADMA Biologics during the fourth quarter valued at $51,000. AlphaQuest LLC purchased a new stake in shares of ADMA Biologics during the fourth quarter valued at $84,000. CIBC Private Wealth Group LLC increased its holdings in ADMA Biologics by 137.1% in the 4th quarter. CIBC Private Wealth Group LLC now owns 5,108 shares of the biotechnology company's stock worth $95,000 after buying an additional 2,954 shares in the last quarter. Finally, Jones Financial Companies Lllp raised its position in ADMA Biologics by 303.4% in the 4th quarter. Jones Financial Companies Lllp now owns 5,733 shares of the biotechnology company's stock worth $98,000 after buying an additional 4,312 shares during the last quarter. Hedge funds and other institutional investors own 75.68% of the company's stock.

Insiders Place Their Bets

In other news, Director Lawrence P. Guiheen sold 7,779 shares of the stock in a transaction on Wednesday, May 21st. The shares were sold at an average price of $20.32, for a total value of $158,069.28. Following the completion of the sale, the director now directly owns 114,830 shares of the company's stock, valued at $2,333,345.60. This represents a 6.34% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Company insiders own 3.50% of the company's stock.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on ADMA. Raymond James lifted their price target on shares of ADMA Biologics from $25.00 to $32.00 and gave the stock a "strong-buy" rating in a research note on Thursday, May 8th. Wall Street Zen downgraded shares of ADMA Biologics from a "hold" rating to a "sell" rating in a research report on Friday, May 9th. Finally, Cantor Fitzgerald reiterated an "overweight" rating and set a $25.00 target price on shares of ADMA Biologics in a research note on Tuesday, March 4th. One equities research analyst has rated the stock with a sell rating, three have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $24.25.

ADMA Biologics Stock Performance

Shares of ADMA traded down $0.48 on Tuesday, reaching $19.94. The company's stock had a trading volume of 1,050,718 shares, compared to its average volume of 3,691,991. The stock's 50 day simple moving average is $20.67 and its two-hundred day simple moving average is $18.89. The company has a debt-to-equity ratio of 0.48, a current ratio of 7.09 and a quick ratio of 3.26. The stock has a market capitalization of $4.76 billion, a P/E ratio of 71.18 and a beta of 0.57. ADMA Biologics, Inc. has a 12-month low of $9.35 and a 12-month high of $25.67.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last issued its quarterly earnings results on Wednesday, May 7th. The biotechnology company reported $0.14 earnings per share for the quarter, missing the consensus estimate of $0.16 by ($0.02). ADMA Biologics had a return on equity of 53.20% and a net margin of 17.80%. The business had revenue of $114.80 million for the quarter, compared to analysts' expectations of $116.40 million. During the same quarter in the prior year, the business earned $0.08 EPS. The company's revenue was up 40.2% compared to the same quarter last year. Research analysts forecast that ADMA Biologics, Inc. will post 0.51 earnings per share for the current fiscal year.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.